SingleCell Biotechnology Unveils High-Throughput Single-Cell Assay Linking Clonal Growth to Molecular Profiles at AACR
Single-cell analysis is rapidly reshaping how researchers understand cancer, particularly in the context of tumor heterogeneity and treatment resistance. At the American Association for Cancer Research (AACR) Annual Meeting 2026, SingleCell Biotechnology unveiled new data that highlight a powerful, scalable approach to studying tumor cell behavior at an unprecedented level of detail. The company’s latest findings demonstrate how high-throughput single-cell assays can bridge the gap between observable cellular behaviors and the molecular mechanisms that drive them—an advance with meaningful implications for oncology research and drug development.
The newly presented data introduce an integrated assay platform designed to measure clonal tumor cell growth across thousands of individual microenvironments simultaneously. Unlike conventional bulk assays that average signals across large populations of cells, this system preserves the full diversity of proliferative behaviors exhibited by individual tumor cells. This distinction is critical because tumors are not uniform masses; they are complex ecosystems composed of diverse cell populations, each with distinct growth patterns, survival strategies, and responses to therapy.
A central focus of the study was the platform’s ability to consistently detect differences in how tumor cells grow under varying conditions. Using multiple models of glioblastoma—one of the most aggressive and treatment-resistant forms of brain cancer—the researchers demonstrated that their assay could reliably capture variability in clonal growth. These differences are often subtle but biologically significant, and they frequently go unnoticed with traditional experimental approaches.
One of the key strengths of the platform lies in its sensitivity to rare or transient cell states. In many cancers, small subpopulations of cells can play an outsized role in disease progression and therapeutic resistance. These cells may exhibit unique molecular signatures or adopt dormant-like states that allow them to survive treatment and later drive relapse. Standard assays, which rely on averaged measurements, tend to obscure these critical subpopulations. In contrast, SingleCell Biotechnology’s approach enables researchers to detect and analyze these rare cell states directly.
Another notable feature of the assay is its ability to track individual cells over time. This longitudinal capability provides a dynamic view of tumor behavior, allowing scientists to observe how specific cells evolve, divide, or respond to environmental changes. By following cells across multiple time points, researchers can begin to map trajectories of growth and adaptation—insights that are essential for understanding how resistance emerges during treatment.
Equally important is the platform’s capacity to recover specific cell populations after observation. Once a subset of interest has been identified—such as cells that exhibit rapid proliferation or resistance-like behavior—those cells can be isolated and subjected to further molecular analysis. This creates a direct link between phenotype (what the cells do) and genotype or molecular profile (what the cells are), enabling a more comprehensive understanding of tumor biology.
The implications of this work are particularly significant in the context of drug development. Tumor heterogeneity has long been recognized as a major obstacle in oncology. Many therapies that appear effective in early testing fail in later stages because they do not adequately target the diverse cell populations within a tumor. By providing a clearer picture of how different cells behave and respond to treatment, high-throughput single-cell assays offer a way to design more effective and targeted therapies.
Traditional preclinical models often rely on measuring average responses across millions of cells. While this approach can provide useful baseline information, it fails to capture the complexity of real tumors. For example, a drug may appear to suppress tumor growth overall, but a small subset of resistant cells may survive and eventually repopulate the tumor. These resistant cells are often the drivers of relapse, yet they remain difficult to study using conventional methods.
The data presented by SingleCell Biotechnology suggest that their platform could help overcome this limitation. By identifying and characterizing the specific cells that contribute to resistance and progression, researchers can gain insights into the mechanisms that underlie these processes. This, in turn, could inform the development of therapies that are better equipped to eliminate not just the bulk of the tumor, but also the critical subpopulations that sustain it.
The scalability of the assay is another important advantage. The ability to analyze thousands of microenvironments in parallel allows researchers to explore a wide range of experimental conditions within a single study. This high-throughput capability accelerates the pace of discovery and enables more comprehensive investigations into how tumor cells interact with their surroundings.
Microenvironmental factors—such as nutrient availability, oxygen levels, and interactions with neighboring cells—play a crucial role in shaping tumor behavior. By recreating diverse microenvironments and observing how individual cells respond, the platform provides valuable insights into the contextual factors that influence growth and survival. This level of detail is essential for understanding how tumors behave in the body, where conditions can vary significantly from one region to another.
The integration of phenotypic and molecular data further enhances the utility of the platform. By combining measurements of cell growth with downstream molecular analyses, researchers can establish direct correlations between observable behaviors and underlying biological processes. This integrated approach represents a significant step forward in the field of functional genomics and precision oncology.
The findings were presented in a poster session at the AACR Annual Meeting, underscoring the growing interest in single-cell technologies within the cancer research community. The presentation, titled “An Integrated High-throughput Assay for Proliferative Phenotypic and Omics,” was delivered by Shiska Raut, a machine learning engineer involved in the project. The inclusion of computational expertise highlights the interdisciplinary nature of modern cancer research, where advances often emerge at the intersection of biology, engineering, and data science.
In summary, the work presented by SingleCell Biotechnology demonstrates a powerful new approach to studying tumor cell behavior. By enabling high-throughput, single-cell analysis of clonal growth across diverse microenvironments, the platform addresses key limitations of traditional assays and provides a more nuanced understanding of tumor heterogeneity. Its ability to capture rare cell states, track individual cells over time, and link phenotypic behaviors to molecular profiles positions it as a valuable tool for both basic research and drug development.
As oncology continues to move toward more personalized and precise treatment strategies, technologies like this are likely to play an increasingly important role. By shedding light on the complexity of tumor biology and revealing the hidden dynamics of cell populations, high-throughput single-cell assays offer a pathway to more effective therapies and improved patient outcomes.
About SingleCell Biotechnology
SingleCell Biotechnology is developing a high-throughput platform to measure tumor cell behavior at single-cell resolution. Its SCI-AP platform integrates microscale assays, automated imaging and machine-learning analysis to quantify tumor cell growth, migration and quiescent states within scalable laboratory workflows. By linking functional phenotypes to molecular signatures, the platform aims to provide deeper insight into tumor heterogeneity and support oncology drug discovery. Founded in 2022, the company is initially focusing on glioblastoma as a model of relapse-driven disease. In 2023, the company received a competitive product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to further advance its platform.
